159752-10-0 Unique Chemicals Sarms For Fat Loss MK-677 Ibutamoren

159752-10-0 Unique Chemicals Sarms For Fat Loss MK-677 Ibutamoren ​

 
1. Product Name: MK-677
2. Synonyms: Ibutamoren
3. CAS: 159752-10-0
4. MF: C28H40N4O8S2
5. MW: 624.77
6. Bp: 868.9 °C at 760 mmHg
7. Fp: 479.3 °C
8. Specific optical rotation: +79.3°
9. Loss on drying: 0.15%
10. Free heptanoic acid: 0.10%
11. Related substances: ≤2%
12. Appearance: white powder
13. Package: 1g; 10g; 100g; 500g; 1kg
14. Storage: At room temperature
 
Usage:
1. An experimental drug meant to control lipids and increase the level of HDL, or good cholesterol, in the bloodstream. A cell-permeable, thiazolyl compound that acts as a potent, high affinity, PPARd agonist.
 
2. Exhibits selectivity for PPARd compared to PPARα and PPARγ. Does not exibit any activity against other nuclear or non-nuclear receptors. Reported to increase cholesterol efflux and ABAC1 expression in macrophages, fibroblasts, and intestinal cells.
 
Application:
1. MK-677 is an orally administrated growth / hormone secretagogue originally developed by Reverse Pharmacology. A secretagogue is the term for a substance that chemically signals for the pituitary gland to secrete .
 
2. In other words, MK-677 could be compared to peptides like GHRP-6 or Ipamorelin, only it doesn't require any injections nor does it have any side effects like GHRP-6. This GHS (Growth / Hormone Secretagogue) was developed in an aim to combat such conditions as muscle wasting, obesity and osteoporosis. It was also targeted towards treatment of elderly hip fracture patients, so there are a myriad of studies done on safety
 
MK-677 COA:
 

 
 
 
 
 
 
 
 
 
 
 
 

 
Other information:

1. Ibutamoren (INN) (developmental code names MK-677, MK-0677, L-163,191) is a non-peptidic, potent, long-acting, orally-active, and selective agonist of the ghrelin receptor and a growth hormone secretagogue,

2. Ibutamoren mimick the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including GH and insulin-like growth factor 1 (IGF-1), but without affecting cortisol levels.

3. It is currently under development as a potential treatment for reduced levels of these hormones, such as in children or elderly adults with growth hormone deficiency and human studies have shown it to increase both muscle mass and bone mineral density,making it a promising therapy for the treatment of frailty in the elderly.It also alters metabolism of body fat and so may have application in the treatment of obesity.

 
Why Choose us ?
 

1. High quality and competitive price
2. Fast and Safest shipping
3. Appreciate after service
4. immediately reply when you have question